Meander Medisch Centrum
Welcome,         Profile    Billing    Logout  
 16 Trials 
15 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Consten, Esther CJ
A1Check, NCT05810207: the External Validation of a Machine Learning Model Predicting Colorectal Anastomotic Leakage

Recruiting
N/A
1000
Europe
Colorectal resection
Freek Daams, SAS Institute
Anastomotic Leak, Anastomotic Leak Large Intestine, Anastomotic Complication, Anastomotic Leak Rectum
07/24
12/24
Bloemendal, Hj
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Dijkhorst-Oei, Lioe-Ting
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight and Obesity
02/29
02/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Completed
2
233
Europe, Japan, US, RoW
LY3473329, Placebo
Eli Lilly and Company
Lipoprotein Disorder
03/24
03/24
Siemerink, E
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
Smet, Bart de
STAP-Delta, NCT04422236: A Post-market, Observational Registry With the easyEndoTM Universal Linear Cutting Stapler in Laparoscopic Bariatric Surgery

Active, not recruiting
N/A
200
Europe
easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Duomed
Obesity, Roux-en-Y Gastric Bypass, Gastrectomy, Mini Gastric Bypass
04/25
05/25
Herder, Judith
NCT03564197: 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

Recruiting
N/A
80
Europe
18F-PD-L1, tracer
The Netherlands Cancer Institute, Bristol-Myers Squibb
NSCLC Stage IV
12/23
12/24
Nes, Anneke van Lynden- van
BioDay, NCT03549416: Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients With Atopic Dermatitis

Recruiting
N/A
1200
Europe
UMC Utrecht, Academisch Ziekenhuis Groningen, Sanofi, AbbVie, Eli Lilly and Company, LEO Pharma
Atopic Dermatitis
12/28
12/28
Dodewaard, JM van
PRO-RCC, NCT05326620: National PROspective Infrastructure for Renal Cell Carcinoma

Recruiting
N/A
2000
Europe
PROspective Renal Cancer Cohort Foundation, Comprehensive Cancer Centre The Netherlands, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Ipsen
Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic
01/30
01/30
Schaik, C van
NCT01898117 / 2013-001484-23: Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
Mosterd, Arend
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
Widener, Nancy
ASTER, NCT05171049 / 2021-003076-14: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Recruiting
3
1655
Europe, Canada, Japan, US, RoW
Abelacimab, MAA868, Apixaban, Eliquis
Anthos Therapeutics, Inc., Itreas
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
06/25
09/25
MAGNOLIA, NCT05171075 / 2021-003085-12: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Recruiting
3
1020
Europe, Canada, US, RoW
Abelacimab, MAA868, Dalteparin, Fragmin
Anthos Therapeutics, Inc., Itreas
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
06/25
09/25
Weel, Vincent van
EASYII, NCT05586503: - E-tegra Stent Graft System - Imaging Cohort

Recruiting
N/A
25
Europe
ECG-gated CTAs
JOTEC GmbH
Vascular Aneurysm
12/23
10/29
Sikkenk, Daan
No trials found
Majoie, Leonie IM
No trials found
Boom, Marije
No trials found

Download Options